ported among women of lower socioeconomic status [9] [10] [11] [12] , women attending sexually transmitted disease (STD) clinics [13] [14] [15] [16] , and homosexual men [17] [18] [19] [20] . Among homosexual men with HlV infection, CMV seropositivity rates approach 100% [19, 20] . High rates of CMV genitourinary tract shedding occur among HIV-seropositive men [19] [20] [21] [22] , and low CD4 cell counts are an independent risk factor for the development of CMV disease in persons with AIDS [3, 23] .
Women accounted for~25% of HIV-infected persons and 18% of all AIDS cases reported in the United States in 1994 [24] . However, epidemiologic and natural history data concerning CMV infection in women are limited primarily to observations regarding the development of CMV disease among small numbers of women with AIDS [3, 23] .
The goals of this study were to examine CMV seroprevalence among HIV-seronegative and HIV-seropositive women from an urban minority community that has a high prevalence of HlV -1 infection and to investigate the relationship between CMV genital tract shedding and selected demographic, behavioral, and clinical characteristics.
Materials and Methods
Studypopulation. This cross-sectional study of 190 HlV-negative and 175 HIV-positive women (table 1) was done between September 1991 and April 1993 at a municipal hospital serving an urban minority population (Brooklyn, NY). The HIV-negative women were enrolled in the Heterosexual AIDS Transmission Study. Each HIV-negative woman had had at least 1 male sex partner in the past year; exclusion criteria were a history or physical examination suggesting intravenous drug use, a positive urine toxi- Microbiologic cultures. Separate Dacron swabs were used to collect endocervical and vulvar specimens for viral culture and were combined in a single vial containing 2 mL of virus transport medium; cultures were done on the day of collection. Briefly, cell culture monolayers (two tubes each ofMRC-5 diploid human lung fibroblasts and A-549 cells; BioWhittaker, Walkersville, MD) were inoculated with 0.2 mL ofvortexed specimen and observed for up to 10 days (HSV) or 6 weeks (CMV) for the development of cytopathic effect. Isolates were identified by immunofluorescence using either a monoclonal antibody to HSV (Syva, San Jose, CA) or CMV immediate-early antigen (Du Pont, Wilmington, DE) [26] .
Endocervical cultures for C. trachomatis were done using cycloheximide-treated McCoy cell monolayers in shell vials (BioWhittaker) and included a blind subpassage. Positive cultures were identified by observing one or more cytoplasmic inclusions after immunofluorescence staining of the cell culture monolayers using a lipopolysaccharide-specific monoclonal antibody (Kallested, Chaska, MN) [27] .
N gonorrhoeae cultures were done by plating cervical swabs on modified Thayer-Martin medium; identification of suggestive colonies was by Gram's staining and screening by the cytochrome oxidase test, with confirmation by the Phadabact coagglutination assay (Pharmacia, Piscataway, NJ).
Vaginal swabs for T. vaginalis culture were placed in Diamond's modified medium (Remel, Lenexa, KS). Culture aliquots were examined microscopically for up to 7 days for the presence of motile trichomonads.
Serologic assays. Serum samples were screened for CMV antibodies using CMVscan (BBL Microbiology Systems, Cockeysville, MD), a passive latex agglutination assay; serum samples from HIV-positive subjects who had positive CMV cultures were tested for IgM antibodies using the CMV CAP-M EIA (BioWhittaker). Serum samples were screened for the presence of antibodies to HIV-1 using the Recombigen EIA (Cambridge Biotech, Worcester, MA); samples positive by EIA were tested by Western blot analysis (Du Pont) and interpreted according to Centers for Disease Control and Prevention guidelines [28] .
Syphilis serology was done using a rapid plasma reagin card test (Becton Dickinson Microbiology Systems, Cockeysville, MD), followed by confirmation of reactive samples by the treponemal MHA-TP assay (Miles Laboratory, Elkhart, IN).
Immunophenotyping was by FACScan analysis of leukocytes stained with a fluorescein isothiocyanate-conjugated monoclonal antibody (Leu 3A; Becton Dickinson, San Jose, CA).
Statistical methods. Univariate analyses for discrete variables were done using the X 2 test (Yates's corrected or X 2 test for trend) or Fisher's exact test. Student's test was used for continuous variables. The Mantel-Haenszel odds ratio was used to summarize risk over subgroups if no significant interactions were found among the groups. Multivariate analyses were done using multiple logistic regression with backward elimination (SPSS, Chicago). Potential interactions among the variables were considered; variables for which P ;;. .10 were excluded from the model.
Results
Study population. HIV-negative and HIV-positive subjects were recruited from the same community but differed in age, ethnicity, place of birth, and drug use; members of both groups had similar socioeconomic status, as measured by annual household income and educational background (table 1). The mean age was 30.3 years for HIV-negative subjects and 33.6 years for HIV-positive subjects (P = .001); 31% ofHIV-nega- Table 2 . CMV seropositivity among HIV-negative and HIV-positive women from an urban minority community.
NOTE. ND, not determined.
* HIV-positive compared with HIV-negative subjects by Mantel-Haenszel method adjusting for each characteristic.
tive and 12% of HIV-positive subjects were <26 years of age (P < .001). HIV-negative subjects were more likely to be black (91.1% vs. 65.7%; P = .001) and to have been born outside the United States (58.9% vs. 24.6%; P < .001); of foreignborn subjects, 95% of HIV-negative and 81% of HIV-positive were from the Caribbean region.
The groups also differed with respect to HIV acquisition risks. HIV-negative subjects were recruited via a study of heterosexual HIV transmission from which intravenous drug users were excluded. HIV-positive subjects were enrolled without regard to transmission risk category; of these, 32.6% reported a history of intravenous drug use. A higher proportion of HIVpositive than HIV-negative subjects reported past (P < .001) or current (P < .001) illicit drug use of any kind.
CMV seroprevalence. Data collected on 190 HIV-negative and 175 Hl'V-positive subjects showed high seropositivity for CMV in both groups: 181 (95.2%) of those HIV-negative and 158 (90.3%) of those HIV-positive (table 2) . CMV seroprevalence was highest among blacks and, for HIV-negative subjects, was significantly higher in black than in Hispanic subjects (97.7% vs. 66.7%; P < .001).
CMV seroprevalence did not vary between HIV-negative and HIV-positive subjects before adjustment or after adjusting for age or ethnicity (table 2) or for the other variables examined (education, annual household income, number of pregnancies, number of recent sex partners, or number of lifetime sex partners; data not shown). Among HIV-positive subjects, CMV seroprevalence did not vary by age at first sexual intercourse or CD4 cell number (data not shown).
CMV shedding. Cervicovaginal shedding was detected in 8 (404%) of 181 HIV-negative and 31 (19.6%) of 158 HIVpositive subjects (odds ratio [OR] = 5.28; P < .001) who were CMV-seropositive (table 3) . CMV shedding remained higher in HIV-positive subjects than in HIV-negative subjects after adjusting individually for differences in a variety of demographic, behavioral, or clinical characteristics between groups (table 3) . Shedding was not detected among CMV-seronegative subjects.
Univariate analysis showed a consistent relationship between shedding and younger age, but this relationship did not reach statistical significance for HIV-negative subjects (P = .10; for HIV-positive subjects, P = .02). Shedding was consistently higher among HIV-positive subjects in all age groups, with 17 (54.8%) of 31 HIV-positive CMV shedders being~30 years old. An association between shedding and concurrent C. trachomatis or N gonorrhoeae infection was observed among HIV-positive subjects (OR = 6.7; P = .05), but univariate analysis failed to show statistical significance for the HIVnegative subjects (OR = 4.0; P = .28).
Current or recent (within prior 12 months) oral contraceptive use appeared to be associated with CMV shedding among HIVpositive subjects (OR = 3.9; P = .04) but not HIV-negative subjects (OR = 1.1; P = 1.0); however, this association was lost after controlling for other variables (age, concurrent STDs, place of birth, pregnancy within prior 12 months). CMV shedding was not significantly associated with the other variables shown in table 3.
Effect ofCD4 cell count on CMV shedding. Viral shedding was associated with decreased CD4 cell numbers in HIV-positive subjects (P = .04; table 3). The prevalence of CMV shedding among HIV-positive subjects with CD4 cell counts of 200 X 106/L was 6.0 times that observed among HIV-negative subjects (P < .001). Among subjects with CD4 cell counts between 201 and 499 X 106/L, shedding was 5.0 times more common than among HIV-negative subjects (P < .001). CMV shedding among HIV-positive subjects with CD4 cell counts 500 X 106/L was not significantly different from that observed for HIV-negative subjects (OR = 1.8; P = AI).
Multiple logistic regression analysis. In a model that included the HIV-negative and HIV-positive subjects who were CMV-seropositive, CMV genital tract shedding was independently associated with younger age and concurrent C. trachomatis or N gonorrhoeae infection (table 4) . Among HIV-positive subjects, shedding was also associated with decreased CD4 cell counts (table 4) .
Other variables that were considered but dropped from the model because they did not reach statistical significance were pregnancy within the past 12 months and current or recent oral contraceptive use.
The association between CMV shedding and CD4 cell count was significantly stronger for foreign-born subjects than for those born in the United States (P < .01; data not shown), and this variable was considered a potential confounder. In a separate logistic model, inclusion of the interaction between place of birth and HIV serostatus about doubled the ORs for CMV shedding by CD4 cell group (~200 X 106/L, OR = We have investigated the rates of CMV seroprevalence and genital tract CMV shedding among HIV-negative and -positive women from an urban minority population with a high prevalence of HIV-1 infection. The overall CMV seroprevalences for these groups exceeded 90%, with the highest rates occurring among black women. Previous studies among predominantly white women attending STD clinics showed an association between CMV seropositivity and several demographic and behavioral characteristics, including age, number of lifetime sex partners, and age at sexual debut [16, 29] . The lack of association between CMV seropositivity and similar characteristics in our study suggests a high degree of prior exposure among the subjects. Although we cannot define the time of CMV acquisition for them, a low rate of primary infection is suggested by the detection of CMV IgM antibody in serum from only 1 (3.2%) of the 31 HIV-positive genital tract CMV shedders described here (data not shown).
Genital tract CMV shedding, detected among 19.6% ofHIVpositive subjects in this cross-sectional study, was associated independently with younger age, concurrent infection with C. trachomatis or N. gonorrhoeae but not T. vaginalis, and CD4 cell counts~200 X 106/L. Data analysis showed that the likelihood of CMV shedding for an HIV-positive woman is 5-6 times greater than for an HIV-negative woman, even after we adjusted for several variables, including age, ethnicity, socioeconomic status (education and income), drug and sexual history, and concurrent STDs.
We observed viral shedding in 26.5% of HIV-positive subjects with CD4 cell counts~200 X 1Q6/L and in 7.9% ofHIVpositive subjects whose CD4 cell counts were~500 X 106/L. These data suggest that more severely irnmunocompromised HIV-positive women may be more likely to contribute to sexual or perinatal transmission of CMV infection than either HIVnegative women or HIV-positive women with CD4 cell counts of ;;.500 X 106/L. We also observed a significantly stronger association between CMV shedding and decreased CD4 cell levels for foreign-born HIV-positive subjects but not for HIVpositive subjects born in the United States. Since place of birth was not considered as a variable in the original study design and because there does not appear to be a biologic basis to support this observation, we elected to exclude this interaction from the current analysis.
In comparing HIV-negative and HIV-positive women for factors associated with CMV shedding, we observed that although shedding occurred at the highest rates among subjects <30 years of age, it occurred over a broad age distribution among HIV-positive subjects. More than half of the HIV-positive subjects exhibiting CMV shedding were ;;'30, with 9 (29%) being between 35 and 46 years of age. These findings are in contrast with those of previous studies in which CMV genital tract shedding occurred almost exclusively in women <30 years of age [14, 30] . Our results provide evidence that age-related local factors (e.g., ectopic changes) do not preclude viral replication, at least among HIV-positive women.
Previous studies of women attending an STD clinic have shown associations between concurrent STDs and CMV genital tract shedding [14, 15] and CMV seropositivity [16] . The results of these studies support the hypothesis that CMV can be acquired through sexual activity. Our finding of an association between certain STDs and CMV shedding, but not seroprevalence, could be explained by the possibility that our subjects were more likely to experience reinfection rather than primary infection with CMV. Alternatively, endocervical C. trachomatis or N gonorrhoeae infection may contribute to reactivation of latent CMV or facilitate its isolation.
Recently it has been shown that persistent CMV shedding in semen of HIV-positive men was associated with an increased risk for the development of AIDS [31] , suggesting that control of CMV infection in infected persons may slow HIV disease progression. Longitudinal studies are underway to investigate patterns of genital tract CMV shedding in the HIV-positive subjects in this study and to examine the relationship between CMV shedding and virologic and clinical markers of HIV disease progression.
